GLP-1 Weight Loss in Reno, NV: Below the State Obesity Rate, and Still Only One Published Price
Reno's obesity rate against Nevada's, Medicaid's unconfirmed obesity coverage, Revenge MD as the only published price, and a thinning endocrinology bench.
Reno's adult obesity rate is 28.4% (BRFSS 2023, crude prevalence, CDC PLACES) 1, 2.4 points below Nevada's same-year 30.8% 2. Nevada's newer 2024 estimate of 34.2% comes from a different survey cycle and is a separate, later data point, not a same-year contrast 2.
Reno has 281,684 residents inside a 575,266-person metro, with a median household income of $85,605 and 10.6% uninsured 345.
Reno does not carry a broad geographic Primary Care HPSA for its general population, but HRSA's current Primary Care shortage-area file (updated 08/27/2026) shows two active designations inside city limits: a Low-Income Population HPSA ("LI - Reno," score 14) covering Census Tract 21.07, designated 05/28/2026, with a 26,557-person designation population and a 4,002:1 population-to-provider ratio; and Community Health Alliance, the city's core FQHC safety-net clinic (680 S Rock Blvd, score 19, designated since 2002). Several facility-based HPSAs (scores 16-18) also serve tribal and HIV-specific populations in Washoe County. Net read: Reno's insured, higher-income population has adequate primary-care access, but its low-income and uninsured residents face a scored, documented shortage that can stand between them and a PCP visit to start or monitor GLP-1 therapy.6
Specialist access
No federal shortage-area category exists for endocrinology (HRSA HPSAs only score primary care, dental, and mental health), so there is no official designation to cite — but real capacity is visibly thinning as GLP-1 demand rises. Renown Health, the region's dominant system, has posted an "Endocrinology Care Transition" notice confirming its University Health-affiliated endocrinology clinic closed, redirecting patients to Northern Nevada Endocrinology or to Renown Medical Group – Endocrinology. Practicing options for Reno-area patients now effectively consolidate to those two group practices; directory aggregators list roughly two dozen Reno-area endocrinologists, but that count is unverified against real scheduling availability, and no sourced new-patient wait-time figure was found — flagged as a gap, not guessed.14
Medicaid coverage note
Nevada Medicaid covers GLP-1s (Ozempic, Mounjaro) for type 2 diabetes with prior authorization — standard under the federal Medicaid Drug Rebate Program. Coverage for the OBESITY indication is unconfirmed and likely absent: KFF's live Medicaid GLP-1 tracker (Jan 2026 data, checked 08/27/2026) explicitly lists Nevada as "Not covered," outside the 13 states (DE, KS, MA, MI, MN, MS, MO, NC, RI, TN, UT, VA, WI) marked "Coverage in place." This contradicts unverified SEO-aggregator claims of a new Jan-2026 NV Preferred Drug List "Anti-Obesity Agents" category; Nevada's own PDL portal returned no fetchable content to confirm or deny it. Bottom line: most Reno residents seeking a GLP-1 for weight loss, regardless of insurance status, are functionally self-pay today.13
Nevada Medicaid: diabetes yes, obesity not confirmed
Nevada Medicaid covers GLP-1s (Ozempic, Mounjaro) for type 2 diabetes with prior authorization, standard under the federal Medicaid Drug Rebate Program. Coverage for the obesity indication is unconfirmed and likely absent: KFF's live Medicaid GLP-1 tracker (Jan 2026 data, checked 08/27/2026) explicitly lists Nevada as "Not covered," outside the 13 states (DE, KS, MA, MI, MN, MS, MO, NC, RI, TN, UT, VA, WI) marked "Coverage in place" 13.
That contradicts unverified SEO-aggregator claims of a new Jan-2026 Nevada Preferred Drug List "Anti-Obesity Agents" category; Nevada's own PDL portal returned no fetchable content to confirm or deny it, so nothing is asserted here. Bottom line: most Reno residents seeking a GLP-1 for weight loss, regardless of insurance status, are functionally self-pay today.
What GLP-1 care costs in Reno today
Only 1 of 9 Reno providers checked publishes any GLP-1 price. Revenge MD's Reno clinic at 10605 Double R Blvd states a $150 start-up fee covering labs and provider consultation, $500/month ongoing with a three-month minimum, or a three-month package paid in full for $1,200, and is explicitly self-pay: "We do not bill insurance for your monthly fee." Its pricing is bundled rather than split by semaglutide versus tirzepatide. Checked on its own site 78.
The rest are call-for-pricing. Ewing Weight Loss Center at 645 Sierra Rose Dr, Ste 103 markets semaglutide, tirzepatide, Zepbound, and Mounjaro prescribing but gates cost behind a required initial consultation 9. Alpine Wellness NV at 10785 Double R Blvd, Suite 101 states plainly that "Program costs vary based on your individual needs and which medications are included in your treatment plan. During your initial consultation, we'll discuss pricing" 10. Reno Weight Loss Clinic publishes non-GLP-1 tiers while omitting GLP-1 pricing 11, and Sierra Advanced Medicine (formerly DŪRM) has a confirmed Reno address and no published GLP-1 price 12.
Astra's price is $68/month for semaglutide and $118/month for tirzepatide, both 12-month plans at $816 and $1,416 annually. It is the national rate, not a Reno offer.
A closed endocrinology clinic and a scored low-income shortage
Reno does not carry a broad geographic Primary Care HPSA for its general population, but HRSA's current Primary Care file (updated 08/27/2026) shows two active designations inside city limits: a Low-Income Population HPSA ("LI - Reno," score 14) covering Census Tract 21.07, designated 05/28/2026, with a 26,557-person designation population and a 4,002:1 population-to-provider ratio; and Community Health Alliance, the city's core FQHC safety-net clinic at 680 S Rock Blvd, score 19, designated since 2002. Several facility-based HPSAs (scores 16-18) also serve tribal and HIV-specific populations in Washoe County 6. Reno's insured, higher-income population has adequate primary-care access; its low-income and uninsured residents face a scored, documented shortage that can stand between them and the PCP visit needed to start or monitor GLP-1 therapy.
No federal shortage category exists for endocrinology, so there is no designation to cite, but capacity is visibly thinning as GLP-1 demand rises. Renown Health, the region's dominant system, has posted an "Endocrinology Care Transition" notice confirming its University Health-affiliated endocrinology clinic closed, redirecting patients to Northern Nevada Endocrinology or Renown Medical Group - Endocrinology 14. Practicing options for Reno-area patients now effectively consolidate to those two group practices; directory aggregators list roughly two dozen area endocrinologists, but that count is unverified against real scheduling availability, and no sourced new-patient wait-time figure was found.
Telehealth answers both the referral squeeze and the price opacity in one step. See the Nevada GLP-1 overview for statewide context.
Astra treats patients in Nevada through state-licensed physicians.
Local options
Revenge MD (Reno location) — The only Reno-area provider found that publishes real GLP-1 pricing on its own site. Reno clinic confirmed at 10605 Double R Blvd, Reno, NV 89521 (Mon–Fri 9:30am–6pm, 775-983-5630). Program page states: $150 start-up fee (labs + provider consultation); $500/mo ongoing ("$50-off new client special," implying $550 standard) with a 3-month minimum; or a 3-month package paid in full for $1,200. Explicitly self-pay: "We do not bill insurance for your monthly fee." Pricing is bundled, not split by semaglutide vs. tirzepatide. Note: the page states the 3-month package saves "$300" in its main body but "$200" in a separate FAQ section further down the same page — Revenge MD's own copy disagrees with itself on the discount size; the $1,200 total, $500/mo, and $150 start-up figures are consistent throughout and are what's cited here. https://www.revengemd.com/weight-loss-glp1-shots/(checked 2026-08-27)
Ewing Weight Loss Center (Reno) — Physical Reno clinic at 645 Sierra Rose Dr, Ste 103, Reno, NV 89511 (775-322-3011). Markets semaglutide/tirzepatide/Zepbound/Mounjaro prescribing but publishes no price for any GLP-1 medication — cost is gated behind a required initial consultation. Representative of Reno's dominant "call for pricing" pattern. https://ewingweightlossclinic.com/reno-weight-loss-center/(checked 2026-08-27)
Alpine Wellness NV (Reno) — Physical Reno clinic at 10785 Double R Blvd, Suite 101, Reno, NV 89521 (775-369-2106). States explicitly: "Program costs vary based on your individual needs and which medications are included in your treatment plan. During your initial consultation, we'll discuss pricing." No GLP-1 price published anywhere on the page. https://www.alpinewellnessnv.com/treatments/glp-1-weight-loss-medications-reno-alpine-wellness/(checked 2026-08-27)
Frequently asked questions
Is Astra cheaper than getting semaglutide or tirzepatide in Reno?
For most Reno patients, yes — often by a wide margin. Astra's national pricing is $68/mo for semaglutide and $118/mo for tirzepatide on a 12-month plan ($816 and $1,416 paid annually), the same price in every city and every dose. Of the Reno-area clinics checked, only one — Revenge MD — publishes a price at all: $500/mo (3-month minimum) or $1,200 for a paid-in-full 3-month package, plus a $150 start-up fee, strictly self-pay and not split out by medication. That puts Revenge MD's monthly rate at roughly 4-5x Astra's tirzepatide price and nearly 7x its semaglutide price. Every other Reno provider checked (Ewing Weight Loss Center, Alpine Wellness NV, and others) requires a phone call or consultation just to learn a price.
Does Nevada Medicaid cover Wegovy or Zepbound in Reno?
Not confirmed, and likely not. Nevada Medicaid does cover GLP-1s like Ozempic and Mounjaro for type 2 diabetes with prior authorization, but KFF's Medicaid GLP-1 tracker (Jan 2026 data) explicitly lists Nevada as "Not covered" for the obesity indication — one of the states outside the 13 that do cover it. Unverified claims on SEO aggregator sites that Nevada added obesity coverage in January 2026 could not be confirmed against Nevada's own Medicaid PDL portal. Until that changes, most Reno residents seeking a GLP-1 for weight loss are self-pay regardless of insurance.
Is Reno's obesity rate higher or lower than the Nevada state average?
Lower, based on the most recent comparable data. Reno's crude adult obesity prevalence is 28.4% (CDC PLACES, BRFSS 2023) versus Nevada's statewide 30.8% for the same year — 2.4 points below the state. That gap may be narrowing: Nevada's newer 2024 BRFSS estimate jumped to 34.2%, but no 2024 or 2025 city-level data exists yet for Reno to confirm whether it moved in step, so this page doesn't compare across mismatched years.
Why won't most Reno weight-loss clinics list their GLP-1 prices online?
It's the norm here, not the exception. Nine physical Reno GLP-1 providers were checked directly on their own websites; only Revenge MD publishes an actual price. The rest — including Ewing Weight Loss Center and Alpine Wellness NV — route pricing to a required phone call or in-person consultation. Alpine Wellness NV's own site puts it plainly: costs "vary based on your individual needs" and are discussed only after a consult.
Are there endocrinologists in Reno for ongoing GLP-1 or diabetes management?
Yes, but the bench is thin and getting thinner. Reno's options have effectively consolidated to two group practices — Northern Nevada Endocrinology and Renown Medical Group – Endocrinology — after Renown Health's University Health-affiliated endocrinology clinic closed and redirected its patients. There's no federal shortage designation for endocrinology specifically, and no verified new-patient wait-time figure exists, but the closure signals tightening specialist capacity even as GLP-1 demand grows.